Education
About Us
Working with TipRanks
Follow Us
VolitionRX (VNRX)
:VNRX
VNRX Stock Chart & Stats
$0.25
$0.01(1.52%)
At close: 4:00 PM EST
$0.25
$0.01(1.52%)
Day’s Range― - ―
52-Week Range$0.22 - $0.94
Previous CloseN/A
Volume29.92K
Average Volume (3M)2.09M
Market Cap
$33.10M
Enterprise Value$34.15M
Total Cash (Recent Filing)$199.41K
Total Debt (Recent Filing)$11.26M
Price to Earnings (P/E)―
Beta0.64
Next Earnings
Mar 31, 2026EPS Estimate
-0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.05
Shares Outstanding130,993,590
10 Day Avg. Volume1,999,122
30 Day Avg. Volume2,091,393
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)-2.08
Price to Sales (P/S)42.09
P/FCF Ratio-1.96
Enterprise Value/Market Cap1.03
Enterprise Value/Revenue23.20
Enterprise Value/Gross Profit23.20
Enterprise Value/Ebitda-1.69
Forecast
1Y Price Target
$2.25Price Target Upside800.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical ValidationInclusion of Nu.Q NETs as the sole biomarker in France's real-world evaluation of early sepsis and the stronger prognostic performance of H3.1 versus established ICU severity scores support the platform's clinical validity and could drive hospital adoption.
Commercial ExpansionDirect sales of the CE-marked Nu.Q NETs assay and potential commercialization of the Nu.Q Vet Feline assay could broaden revenue sources beyond veterinary products and open new clinical and veterinary markets.
Strategic PartnershipsAgreements with Werfen and a co-marketing and services arrangement with Hologic, combined with management's expectation of additional licensing deals, position the company to scale distribution through large diagnostic partners.
Bears Say
Balance Sheet RiskLow cash levels, a high cash burn rate, and negative working capital increase the likelihood that additional financing will be required, creating dilution and execution risk for the company.
Capital Structure ConcernsFinancing overhang and negative shareholders' equity have prompted analyst downgrades and could weigh on the stock until the company's capital structure is stabilized.
Partnership Execution UncertaintyHigh uncertainty around the timing and structure of planned partnership deals makes revenue forecasts inconsistent and raises execution risk for growth plans.
VolitionRX News
VNRX FAQ
What was VolitionRX’s price range in the past 12 months?
VolitionRX lowest stock price was $0.22 and its highest was $0.94 in the past 12 months.
What is VolitionRX’s market cap?
VolitionRX’s market cap is $33.10M.
When is VolitionRX’s upcoming earnings report date?
VolitionRX’s upcoming earnings report date is Mar 31, 2026 which is in 47 days.
How were VolitionRX’s earnings last quarter?
VolitionRX released its earnings results on Nov 13, 2025. The company reported -$0.05 earnings per share for the quarter, missing the consensus estimate of -$0.044 by -$0.006.
Is VolitionRX overvalued?
According to Wall Street analysts VolitionRX’s price is currently Undervalued.
Does VolitionRX pay dividends?
VolitionRX does not currently pay dividends.
What is VolitionRX’s EPS estimate?
VolitionRX’s EPS estimate is -0.04.
How many shares outstanding does VolitionRX have?
VolitionRX has 130,993,590 shares outstanding.
What happened to VolitionRX’s price movement after its last earnings report?
VolitionRX reported an EPS of -$0.05 in its last earnings report, missing expectations of -$0.044. Following the earnings report the stock price went down -6.497%.
Which hedge fund is a major shareholder of VolitionRX?
Currently, no hedge funds are holding shares in VNRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
VolitionRX Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$2.25 (800.00% Upside)
$2.25 (800.00% Upside)
Blogger Sentiment
Bullish
VNRX Sentiment 100%
Sector Average 69%
Sector Average 69%
Insider Transactions
Bought Shares
Worth $7.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.7%
Last 30 Days ▼ 1.3%
Last 30 Days ▼ 1.3%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-58.00%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-49.14%
Trailing 12-Months
Company Description
VolitionRX
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. It sells Nu.Q that detect cancer; Nu.Q Nets, monitoring the immune system; Nu.Q Vet cancer screening test for veterinary applications; Nu.Q Capture capturing and concentrating samples for more accurate diagnosis; and Nu.Q Discover, a solution to profiling nucleosomes. The company operates Nucleosomics a technology platform for blood test. VolitionRx Limited is based in Austin, Texas.
VNRX Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in revenue growth, cost management, and strategic partnerships with major companies like Werfen and Hologic. Scientific advancements also promise future potential. However, challenges remain, such as unpredictable revenue and uncertainty in closing additional licensing agreements.View all VNRX earnings summariesVNRX Stock 12 Month Forecast
Average Price Target
$2.25
▲(800.00% Upside)
Technical Analysis
Ownership Overview
10.40% Insiders
1.37% Mutual Funds
0.20% Other Institutional Investors
87.20% Public Companies and
Individual Investors